Galapagos Shares Updated ATALANTA-1 Results At ASH 2025 Showing High Response Rates And Durable Responses With GLPG5101 In MCL

Benzinga · 2d ago

High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time